203 related articles for article (PubMed ID: 28302100)
1. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
[TBL] [Abstract][Full Text] [Related]
2. Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose.
Muñoz M; Parrilla J; Rosso M; Coveñas R
Acta Derm Venereol; 2019 May; 99(6):620-621. PubMed ID: 30734049
[No Abstract] [Full Text] [Related]
3. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.
Booken N; Heck M; Nicolay JP; Klemke CD; Goerdt S; Utikal J
Br J Dermatol; 2011 Mar; 164(3):665-7. PubMed ID: 21039410
[No Abstract] [Full Text] [Related]
4. Aprepitant for the Treatment of Chronic Refractory Pruritus.
He A; Alhariri JM; Sweren RJ; Kwatra MM; Kwatra SG
Biomed Res Int; 2017; 2017():4790810. PubMed ID: 29057261
[TBL] [Abstract][Full Text] [Related]
5. [Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma].
Palacios Zabalza I; López de Torre Querejazu A; Santos Ibañez A
Farm Hosp; 2014 Apr; 38(2):145-7. PubMed ID: 24669900
[TBL] [Abstract][Full Text] [Related]
6. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma.
Borja-Consigliere HA; López-Pestaña A; Vidal-Manceñido MJ; Tuneu-Valls A
Actas Dermosifiliogr; 2014 Sep; 105(7):716-8. PubMed ID: 24139470
[No Abstract] [Full Text] [Related]
9. Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
Ladizinski B; Bazakas A; Olsen EA
J Am Acad Dermatol; 2012 Nov; 67(5):e198-9. PubMed ID: 23062910
[No Abstract] [Full Text] [Related]
10. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Santini D; Vincenzi B; Guida FM; Imperatori M; Schiavon G; Venditti O; Frezza AM; Berti P; Tonini G
Lancet Oncol; 2012 Oct; 13(10):1020-4. PubMed ID: 22995650
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case report.
Villafranca JJ; Siles MG; Casanova M; Goitia BT; Domínguez AR
J Med Case Rep; 2014 Sep; 8():300. PubMed ID: 25200537
[TBL] [Abstract][Full Text] [Related]
12. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
Ständer S; Siepmann D; Herrgott I; Sunderkötter C; Luger TA
PLoS One; 2010 Jun; 5(6):e10968. PubMed ID: 20532044
[TBL] [Abstract][Full Text] [Related]
13. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
Costantini VJ; Corsi M; Dünstl G; Bettelini L; Zonzini L; Gerrard P
Exp Dermatol; 2015 Apr; 24(4):312-4. PubMed ID: 25650546
[TBL] [Abstract][Full Text] [Related]
14. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.
Maroñas-Jiménez L; Estrach T; Gallardo F; Pérez A; Andrés Borja H; Servitje O; Pérez Gala S; Linares Barrio M; Jiménez Gallo D; Sanz-Bueno J; Lora D; Monsálvez V; Ortiz-Romero PL
Br J Dermatol; 2018 Apr; 178(4):e273-e274. PubMed ID: 29150837
[No Abstract] [Full Text] [Related]
16. NK-1 Antagonists and Itch.
Ständer S; Luger TA
Handb Exp Pharmacol; 2015; 226():237-55. PubMed ID: 25861784
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant for erlotinib-induced pruritus.
Levêque D
N Engl J Med; 2010 Oct; 363(17):1680-1; author reply 1681. PubMed ID: 20961258
[No Abstract] [Full Text] [Related]
18. Pruritus in Cutaneous T-Cell Lymphoma and Its Management.
Serrano L; Martinez-Escala ME; Zhou XA; Guitart J
Dermatol Clin; 2018 Jul; 36(3):245-258. PubMed ID: 29929596
[TBL] [Abstract][Full Text] [Related]
19. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.
Poligone B; Rubio-Gonzalez B; Querfeld C
Dermatol Ther; 2019 Mar; 32(2):e12804. PubMed ID: 30549384
[TBL] [Abstract][Full Text] [Related]
20. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.
Tebas P; Spitsin S; Barrett JS; Tuluc F; Elci O; Korelitz JJ; Wagner W; Winters A; Kim D; Catalano R; Evans DL; Douglas SD
AIDS; 2015 May; 29(8):931-9. PubMed ID: 25915168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]